Vimarsana
Biggest News Aggregation in the World

Page 3 - Frx News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Frx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Frx Today - Breaking & Trending Today

Gold's Fickleness Makes It Bitcoin For Boomers - Vimarsana News

Gold's Fickleness Makes It Bitcoin For Boomers

The yellow metal has become untethered from financial fundamentals.

Moody's Cuts Outlook For Chinese Banks, Hong Kong, LGFVs - Vimarsana News

Moody's Cuts Outlook For Chinese Banks, Hong Kong, LGFVs

Moody’s Investors Service cut its outlook for eight Chinese banks to negative from stable, a day after unveiling a bearish stance on the nation’s sovereign bonds due to concern over the level of debt.

Japan Output Rises More Than Expected on Autos, Electronics - Vimarsana News

Japan Output Rises More Than Expected on Autos, Electronics

Japan’s industrial production rose more than expected in October, offering a fresh sign of economic resilience as improvement in supply chains bolstered automakers and inventory adjustments underpinned the electronics parts industry.

Fennec Pharmaceuticals Inc. (TSE:FRX) Director Khalid Islam Acquires 20,492 Shares - Vimarsana News

Fennec Pharmaceuticals Inc. (TSE:FRX) Director Khalid Islam Acquires 20,492 Shares

Fennec Pharmaceuticals Inc. (TSE:FRX – Get Free Report) Director Khalid Islam purchased 20,492 shares of Fennec Pharmaceuticals stock in a transaction that occurred on Thursday, November 16th. The shares were bought at an average cost of C$2.44 per share, for a total transaction of C$50,000.48. Fennec Pharmaceuticals Stock Up 2.5 % Shares of TSE:FRX opened […]

InflaRx Reports Positive Topline Results From SAD Phase I Study With C5aR Inhibitor INF904 - Vimarsana News

InflaRx Reports Positive Topline Results From SAD Phase I Study With C5aR Inhibitor INF904

Biotechnology company InflaRx N.V. (IFRX) announced Monday topline results from the single ascending dose (SAD) part of its randomized, double-blind, placebo-controlled Phase I trial of the orally administered, low molecular weight C5aR inhibitor INF904.